Table 3 Comparison of clinical data in patients with CAD in the low HGS group and the normal HGS group.

WBC, 10^⁹/L

5.51(4.65, 6.98)

5.79(4.87, 7.14)

−0.703^a

RBC, 10^¹²/L

4.23 ± 0.62

4.60 ± 0.41

3.243^b

Hb, g/L

133.00(116.00, 141.00)

144.50(133.50, 153.75)

−3.266^a

NEU, 10^⁹/L

3.87(2.92, 4.90)

3.65(2.99, 4.79)

−0.204^a

LYM, 10^⁹/L

1.19(0.93, 1.51)

1.42(1.17, 1.66)

−1.659^a

ALB, g/L

41.83 ± 3.52

44.64 ± 2.45

4.226^b

UA, μmol/L

353.57 ± 86.59

364.22 ± 84.01

0.557^b

Scr, μmol/L

73.90(63.65, 95.95)

70.50(63.78, 87.88)

−0.556^a

GGT, U/L

24.00(19.50, 37.00)

23.50(19.00, 38.75)

−0.024^a

ChE, U/L

8311.69 ± 2662.81

8983.58 ± 1550.16

1.974^b

TG, mmol/L

1.38(1.08, 1.89)

1.46(1.09, 2.25)

−0.737^a

TC, mmol/L

3.74 ± 1.11

3.68 ± 0.95

−0.254^b

HDL-C, mmol/L

1.11(0.91, 1.29)

1.03(0.83, 1.29)

−0.746^a

LDL-C, mmol/L

2.11(1.22, 2.87)

1.94(1.54, 2.36)

−0.190^a

CAD duration, years

2.50(0.25, 6.00)

1.00(1.00, 4.13)

−0.689^a

Hypertension

34(75.6%)

25(69.4%)

0.378^c

Type 2 diabetes

15(33.3%)

12(33.3%)

0^c

COPD

3(6.7%)

2(5.6%)

−^d

Long-term medications, species

4(3, 6)

5(3, 6)

−0.376^a

FTSST, s

15.98(12.14, 20.86)

12.51(10.27, 14.31)

−3.678^a

GS, m/s

0.90 ± 0.27

1.14 ± 0.24

4.080^b

CC, cm

32.24 ± 3.22

35.15 ± 2.58

4.409^b

SARC-F

1(0, 2)

0(0, 1)

−2.333^a

Body fat mass, kg

16.62 ± 6.82

19.08 ± 5.96

1.705^b

Body fat percentage, %

29.30(21.00, 32.35)

27.75(21.20, 33.05)

−0.076^a

WHR

0.93(0.88, 0.97)

0.95(0.92, 0.96)

−1.048^a

ASM, kg

17.19 ± 4.22

20.78 ± 4.70

3.616^b

ASMI, kg·m⁻²

6.75 ± 1.12

7.42 ± 1.11

2.662^b